Large B-cell Lymphoma Clinical Trial
Official title:
Expanded Access Program (EAP) to Provide Epcoritamab (GEN3013) to Eligible Patients With Relapsed or Refractory Large B-cell Lymphoma
NCT number | NCT05733650 |
Other study ID # | GCT3013-101 |
Secondary ID | |
Status | Approved for marketing |
Phase | |
First received | |
Last updated |
Verified date | May 2023 |
Source | Genmab |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Expanded Access |
The purpose of this program is to provide investigational epcoritamab, an antibody also known as GEN3013 (DuoBody-CD3xCD20), in an expanded access setting for eligible patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) who have a high unmet medical need with no other treatment options. It is a requirement that patients do not qualify for an ongoing epcoritamab clinical program or are unable to participate due to logistical reasons. Access to investigational epcoritamab can be requested by contacting preapprovalaccessprograms@genmab.com.
Status | Approved for marketing |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Must be 18 years of age or older - R/R CD20+ mature B-cell neoplasm - Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0, 1, or 2 - = 2 prior lines of antineoplastic therapy, including = 1 anti-CD20 monoclonal antibody (mAb) - Fluorodeoxyglucose (FDG) positron emission tomography (PET)-avid and measurable disease by computed tomography/magnetic resonance imaging (CT/MRI) - Patients considering the EAP should have no other available therapeutic option and cannot be eligible for other epcoritamab trials. - Patients considering the EAP must be located in proximity to a US site given that the EAP is currently available only in the United States. - Prior to initiating any program-related assessments or procedures, patients (or their legally acceptable representative) must sign an informed consent form (ICF), which indicates the purpose of the program, the procedures required for the program, and confirms the patient's willingness to participate in the program. Exclusion Criteria: - Any prior therapy with an investigational bispecific antibody targeting CD3 and CD20 - Prior treatment with CAR-T therapy within 100 days prior to first epcoritamab administration - Primary central nervous system (CNS) lymphoma or known CNS involvement by lymphoma - Confirmed history of or current autoimmune disease or other diseases resulting in permanent immunosuppression or requiring permanent immunosuppressive therapy. Low-dose prednisolone for rheumatoid arthritis or similar conditions is allowed. - Active hepatitis B or hepatitis C - Known clinically significant cardiac disease - Pregnancy or breastfeeding - Known hypersensitivity to allopurinol or rasburicase |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Genmab | AbbVie |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05929716 -
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT05464719 -
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
|
Phase 2 | |
Recruiting |
NCT06047080 -
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
|
Phase 3 | |
Active, not recruiting |
NCT04566978 -
89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)
|
Early Phase 1 | |
Recruiting |
NCT06104592 -
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
|
Phase 2 | |
Recruiting |
NCT04889716 -
CAR-T Followed by Bispecific Antibodies
|
Phase 2 | |
Recruiting |
NCT04250324 -
Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT05326243 -
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05794958 -
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
|
Phase 1 | |
Recruiting |
NCT06285422 -
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
|
Phase 1 | |
Recruiting |
NCT05404048 -
PD-L1 PET-imaging During CAR T-cell Therapy
|
Phase 2 | |
Recruiting |
NCT06375733 -
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
|
Phase 1/Phase 2 | |
Recruiting |
NCT05887167 -
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
|
Phase 1 | |
Recruiting |
NCT05648019 -
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
|
Phase 2 | |
Recruiting |
NCT05643742 -
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05820841 -
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Recruiting |
NCT05472610 -
Study of Efficacy of BZ019 in Large B-cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT03960840 -
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL
|
Phase 1/Phase 2 | |
Recruiting |
NCT06356129 -
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
|
Phase 3 | |
Recruiting |
NCT05665062 -
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
|
Phase 1 |